Pomalidomide-amido-C1-Br is primarily utilized in the field of medicinal chemistry and drug development, particularly in the synthesis of targeted therapies. It serves as a key intermediate in the production of proteolysis-targeting chimeras (PROTACs), which are innovative compounds designed to degrade specific disease-causing proteins. This chemical is instrumental in creating molecules that can selectively bind to both the target protein and an E3 ubiquitin ligase, leading to the protein's ubiquitination and subsequent degradation by the proteasome. Its application is especially relevant in cancer research, where it aids in the development of treatments for conditions such as multiple myeloma and other hematologic malignancies. Additionally, its role in the modification of pomalidomide derivatives enhances the efficacy and specificity of therapeutic agents, contributing to advancements in precision medicine.